دورية أكاديمية
أعرض في EDS

The Association Between Human Immunodeficiency Virus and Bacterial Vaginosis and Metronidazole Treatment Failure for Trichomonas vaginalis.

التفاصيل البيبلوغرافية
العنوان: The Association Between Human Immunodeficiency Virus and Bacterial Vaginosis and Metronidazole Treatment Failure for Trichomonas vaginalis.
المؤلفون: Frechtling D; From the John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA., Chopra S; Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA., Ratnayake A; Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA., Kissinger PJ; Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.
المصدر: Sexually transmitted diseases [Sex Transm Dis] 2024 Jan 01; Vol. 51 (1), pp. 61-64. Date of Electronic Publication: 2023 Oct 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: J B Lippincott Country of Publication: United States NLM ID: 7705941 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-4521 (Electronic) Linking ISSN: 01485717 NLM ISO Abbreviation: Sex Transm Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia Pa : J B Lippincott
Original Publication: Philadelphia, Lippincott.
مواضيع طبية MeSH: Trichomonas vaginalis* , Vaginosis, Bacterial*/complications , Vaginosis, Bacterial*/drug therapy , Trichomonas Vaginitis*/complications , Trichomonas Vaginitis*/drug therapy , HIV Infections*, Female ; Humans ; Metronidazole/therapeutic use ; HIV ; Treatment Failure
مستخلص: Background: Trichomonas vaginalis (TV) is a common sexually transmitted infection. High rates of repeated infections have been observed, particularly among women living with human immunodeficiency virus (HIV). Trichomonas vaginalis frequently cooccurs with bacterial vaginosis (BV). The purpose of this study was to determine if coinfections with TV, BV, and HIV could lead to differential treatment failure outcomes.
Methods: Data were pooled from 2 prior randomized control trials comparing 2 g oral single-dose versus 500-mg twice daily oral 7-day dose metronidazole for the treatment of TV in HIV infected and HIV uninfected women. Trichomonas vaginalis rates 1-month postcompletion of treatment were compared by arm, HIV and BV status after removing those who had sexual reexposure, and/or did not complete their treatment.
Results: Data for 795 subjects were included in the study, of which 76 (9.6%) experienced treatment failure. In the final multivariable model, which included treatment dose, HIV status, and BV status, odds of treatment failure infection in the 7-day dose group were lower than the odds in the single dose group (odds ratio, 040; 95% confidence interval, 0.23-0.68). Treatment failure was lower in the multidose arm compared with single dose for both HIV-infected (4.0% vs 10.3%; P = 0.0568) and HIV-uninfected (7.3% vs 15.4%; P = 0.0037). Neither HIV nor BV was associated with higher treatment failure.
Conclusions: Human immunodeficiency virus infection and BV status did not significantly alter the rate of repeat infection for either single dose or 7-day dose metronidazole. Among all women, 7-day metronidazole lowered the odds of treatment failure.
Competing Interests: Conflict of Interest: None declared.
(Copyright © 2023 American Sexually Transmitted Diseases Association. All rights reserved.)
References: Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 2015; 10:e0143304.
Van Gerwen OT, Craig-Kuhn MC, Jones AT, et al. Trichomoniasis and adverse birth outcomes: A systematic review and meta-analysis. BJOG 2021; 128:1907–1915.
Silver BJ, Guy RJ, Kaldor JM, et al. Trichomonas vaginalis as a cause of perinatal morbidity: A systematic review and meta-analysis. Sex Transm Dis 2014; 41:369–376.
Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The vaginal infections and prematurity study group. Sex Transm Dis 1997; 24:353–360.
Swygard H, Seña AC, Hobbs MM, et al. Trichomoniasis: Clinical manifestations, diagnosis and management. Sex Transm Infect 2004; 80:91–95.
Masha SC, Cools P, Sanders EJ, et al. Trichomonas vaginalis and HIV infection acquisition: A systematic review and meta-analysis. Sex Transm Infect 2019; 95:36–42.
Kissinger P, Adamski A. Trichomoniasis and HIV interactions: A review. Sex Transm Infect 2013; 89:426–433.
Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 2002; 34:519–522.
Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008; 46:994–999.
Krashin JW, Koumans EH, Bradshaw-Sydnor AC, et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sex Transm Dis 2010; 37:440–444.
Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: A randomized controlled trial. Sex Transm Dis 2006; 33:445–450.
Tidwell BH, Lushbaugh WB, Laughlin MD, et al. A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of Trichomonal vaginitis . J Infect Dis 1994; 170:242–246.
Spence MR, Harwell TS, Davies MC, et al. The minimum single oral metronidazole dose for treating trichomoniasis: A randomized, blinded study. Obstet Gynecol 1997; 89:699–703.
Woodcock KR. Treatment of trichomonal vaginitis with a single oral dose of metronidazole. Br J Vener Dis 1972; 48:65–68.
Thin RN, Symonds MA, Booker R, et al. Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis. Br J Vener Dis 1979; 55:354–356.
Hager WD, Brown ST, Kraus SJ, et al. Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens. JAMA 1980; 244:1219–1220.
duBouchet L, Spence MR, Rein MF, et al. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis 1997; 24:156–160.
Fleury FJ, Van Bergen WS, Prentice RL, et al. Single dose of two grams of metronidazole for Trichomonas vaginalis infection. Am J Obstet Gynecol 1977; 128:320–323.
Balkus JE, Richardson BA, Rabe LK, et al. Bacterial vaginosis and the risk of Trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis 2014; 41:123–128.
Gatski M, Martin DH, Clark RA, et al. Co-occurrence of Trichomonas vaginalis and bacterial vaginosis among HIV-positive women. Sex Transm Dis 2011; 38:163–166.
van de Wijgert JHHM, Morrison CS, Brown J, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African women. Sex Transm Dis 2009; 36:357–364.
Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: Association with increased acquisition of HIV. AIDS 1998; 12:1699–1706.
Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350:546–550.
Centers for Disease C, Prevention. 2015 STD Treatment Guidelines 2015.
Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: Single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:565–571.
Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: An open-label, randomised controlled trial. Lancet Infect Dis 2018; 18:1251–1259.
Balkus JE, Richardson BA, Mochache V, et al. A prospective cohort study comparing the effect of single-dose 2g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis 2013; 40:499–505.
المشرفين على المادة: 140QMO216E (Metronidazole)
تواريخ الأحداث: Date Created: 20231103 Date Completed: 20231218 Latest Revision: 20240109
رمز التحديث: 20240110
DOI: 10.1097/OLQ.0000000000001891
PMID: 37921835
قاعدة البيانات: MEDLINE
الوصف
تدمد:1537-4521
DOI:10.1097/OLQ.0000000000001891